•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock
Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares
Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock
Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
Pharvaris' genetic disorder drug meets main goal in late-stage trial
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS
Already premium?